Wegener's Granulomatosis (Granulomatosis with Polyangiitis)
What is Wegener's granulomatosis (granulomatosis with polyangiitis)?
Granulomatosis with polyangiitis (GPA), historically called Wegener’s granulomatosis, is a rare, autoimmune vasculitis that primarily affects small‑ and medium‑sized blood vessels. The disease is characterized by necrotizing (tissue‑destroying) inflammation of the blood vessels, formation of granulomas (clusters of immune cells), and a predisposition to cause damage in the respiratory tract (and often the kidneys). GPA belongs to a group of conditions known as ANCA‑associated vasculitides because most patients have circulating anti‑neutrophil cytoplasmic antibodies (ANCA), usually directed against proteinase‑3 (PR3‑ANCA).
Although the exact cause remains unknown, the immune system mistakenly attacks the body’s own vessels, leading to swelling, scarring, and loss of function in the affected organs. Early recognition and treatment are essential to prevent irreversible organ damage.
Common Causes
GPA is not caused by a single factor; rather, a combination of genetic susceptibility, environmental triggers, and immune dysregulation appears to set the disease in motion. The following factors are commonly associated with the development or flare‑up of GPA:
- Genetic predisposition: Certain HLA‑DQ and HLA‑DR alleles increase risk.
- ANCA antibodies: Presence of PR3‑ANCA (c‑ANCA) is a hallmark of the disease.
- Infections: Chronic exposure to Staphylococcus aureus or viral infections (e.g., influenza, hepatitis B) may trigger immune activation.
- Silica dust exposure: Occupational inhalation of silica (mining, sandblasting) has been linked to higher rates of vasculitis.
- Medications: Rarely, drugs such as propylthiouracil, hydralazine, or cocaine adulterated with levamisole can induce ANCA‑associated vasculitis.
- Smoking: Tobacco use is associated with increased disease severity and relapse rates.
- Environmental pollutants: Long‑term exposure to diesel exhaust or other airborne particulates may contribute.
- Seasonal variation: Some studies suggest higher incidence in winter months, possibly related to viral upper‑respiratory infections.
- Previous autoimmune disease: Patients with other autoimmune conditions (e.g., rheumatoid arthritis, lupus) have a slightly higher risk.
- Age and sex: GPA most often presents between ages 40–60 and is slightly more common in men.
Associated Symptoms
Because GPA can involve several organ systems, symptoms are often diverse and may evolve over time. The classic triad involves the upper respiratory tract, lower respiratory tract, and kidneys.
- Upper airway: Nasal congestion, chronic sinusitis, epistaxis (nosebleeds), crusting, or saddle‑nose deformity from cartilage destruction.
- Lower airway: Cough, hemoptysis (coughing up blood), shortness of breath, wheezing, or chest pain.
- Kidneys: Hematuria (blood in urine), proteinuria, flank pain, or rapidly progressive glomerulonephritis leading to renal failure.
- General: Fever, fatigue, weight loss, night sweats, and malaise.
- Eyes and ears: Conjunctivitis, scleritis, hearing loss, or tinnitus.
- Skin: Palpable purpura, livedo reticularis, or ulcerating nodules.
- Neurologic: Paresthesias, mononeuritis multiplex, or, rarely, central nervous system involvement causing seizures.
- Joint involvement: Arthralgia or transient arthritis without permanent damage.
When to See a Doctor
Because early treatment can preserve organ function, seek medical attention promptly if you notice:
- Persistent sinus pain or nosebleeds that do not improve with typical sinus‑infection treatment.
- Coughing up blood or unexplained shortness of breath.
- Blood in the urine, especially if accompanied by swelling in the legs or foamy urine.
- Unexplained fever, night sweats, or weight loss lasting more than two weeks.
- New skin lesions that are painful, purplish, or ulcerated.
- Sudden loss of hearing or severe eye pain/redness.
These signs may represent the early phase of GPA or another serious condition that needs evaluation.
Diagnosis
Diagnosing GPA requires a combination of clinical assessment, laboratory testing, imaging, and often a tissue biopsy.
Laboratory Tests
- ANCA testing: Positive PR3‑ANCA (c‑ANCA) is found in 70–90 % of active GPA cases. A negative result does not rule out the disease.
- Complete blood count (CBC): May show anemia, leukocytosis, or eosinophilia.
- Renal panel: Elevated creatinine or reduced eGFR suggests kidney involvement.
- Urinalysis: Presence of red blood cells, red‑cell casts, or protein.
- Inflammatory markers: ESR and CRP are usually elevated.
Imaging Studies
- Chest X‑ray or CT scan: Detects nodules, cavitary lesions, or infiltrates.
- Sinus CT: Shows mucosal thickening, bony erosion, or polyps.
- Renal ultrasound: Assesses kidney size and cortical thickness.
Biopsy
A tissue sample from the affected organ (usually nasal mucosa, lung, or kidney) is the gold standard. The hallmark finding is necrotizing granulomatous inflammation with vasculitis.
Classification Criteria
The 2022 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria assign points for ANCA positivity, histopathology, and clinical features. A score ≥5 classifies the patient as having GPA.1
Treatment Options
The therapeutic goal is to induce remission quickly, then maintain it with the lowest effective drug dose to limit toxicity. Treatment is usually coordinated by a rheumatologist, pulmonologist, and nephrologist.
Induction Therapy (First 3–6 months)
- High‑dose glucocorticoids: Prednisone 1 mg/kg/day (max 60 mg) tapered over weeks.
- Immunosuppressive agents:
- Rituximab: Anti‑CD20 monoclonal antibody (375 mg/m² weekly ×4 or 1 g ×2 weeks). Shown to be non‑inferior to cyclophosphamide and preferred in patients with renal involvement or fertility concerns.
- Cyclophosphamide: Oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2–3 weeks) for severe disease; limited to 3–6 months due to risk of bladder toxicity.
- Avacopan: Oral C5a receptor inhibitor approved in 2021, used with reduced glucocorticoid exposure.
- Plasma exchange (PLEX): Considered for rapidly progressive glomerulonephritis or diffuse alveolar hemorrhage (limited evidence but recommended in certain high‑risk cases).
Maintenance Therapy (After remission)
- Rituximab: 500 mg IV every 6 months for 2–4 years, or low‑dose regimen.
- Azathioprine: 2–2.5 mg/kg/day.
- Mycophenolate mofetil: 1–1.5 g twice daily (alternative for those intolerant to azathioprine).
- Low‑dose glucocorticoids: Usually ≤5 mg prednisone daily after taper.
Supportive & Home Care
- Vaccinations: Influenza, COVID‑19, pneumococcal, and hepatitis B before starting immunosuppression.
- Infection prevention: Hand hygiene, avoiding crowded places when immunosuppressed.
- Bone health: Calcium + vitamin D supplementation and a bisphosphonate if on long‑term steroids.
- Regular monitoring: Blood work every 2–4 weeks during induction, then every 3–6 months.
- Lifestyle: Smoke‑free, balanced diet, and moderate exercise to maintain cardiovascular health.
Prevention Tips
Because GPA’s exact cause is unknown, true primary prevention is not possible, but several measures can reduce risk of triggering a flare or developing complications:
- Quit smoking and avoid exposure to second‑hand smoke.
- Use protective equipment (respirators, masks) in jobs with silica or heavy dust exposure.
- Promptly treat chronic sinus infections and follow up with an ENT specialist.
- Stay up‑to‑date with vaccinations before immunosuppression.
- Inform healthcare providers about any new medications, especially propylthiouracil, hydralazine, or cocaine.
- Maintain regular follow‑up appointments for blood monitoring and ANCA testing.
- Adopt a low‑salt diet and control blood pressure to protect kidney function.
Emergency Warning Signs
- Sudden, severe shortness of breath or chest pain that worsens rapidly.
- Massive hemoptysis (coughing up large amounts of blood).
- Rapidly decreasing urine output or swelling of both legs indicating acute kidney failure.
- Sudden vision loss, severe eye pain, or eye swelling.
- Profound, unexplained fever (>39 °C / 102 °F) with chills.
- Severe, unrelenting headache or neurological changes (confusion, weakness on one side, seizures).
These situations may signal life‑threatening organ involvement and require immediate treatment.
Key Takeaways
- GPA is a rare, autoimmune vasculitis that can damage the nose, lungs, kidneys, and other organs.
- Early recognition of symptoms—especially persistent sinus issues, cough with blood, or abnormal urine—can save organ function.
- Diagnosis relies on ANCA testing, imaging, and a confirming biopsy.
- Modern therapy (rituximab, avacopan, and carefully tapered steroids) can achieve remission in most patients.
- Long‑term monitoring and lifestyle measures are essential to prevent relapses and treatment complications.
For personalized advice, always discuss your symptoms and treatment plan with a qualified rheumatologist or your primary care physician. If you notice any emergency warning signs, seek care immediately.
Sources:
- American College of Rheumatology/European League Against Rheumatism. 2022 Classification Criteria for GPA. Arthritis Rheumatol. 2022;74(5):752‑764.
- Mayo Clinic. Granulomatosis with polyangiitis (Wegener's). https://www.mayoclinic.org
- Cleveland Clinic. Wegener’s Granulomatosis (Granulomatosis with Polyangiitis). https://my.clevelandclinic.org
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. Wegener’s Granulomatosis. https://www.niams.nih.gov
- World Health Organization. WHO classification of vasculitis. https://www.who.int